Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Descriptor ID |
D003602
|
MeSH Number(s) |
G12.287
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 7 | 9 |
1995 | 2 | 2 | 4 |
1996 | 5 | 8 | 13 |
1997 | 1 | 5 | 6 |
1998 | 2 | 5 | 7 |
1999 | 3 | 5 | 8 |
2000 | 2 | 8 | 10 |
2001 | 1 | 3 | 4 |
2002 | 2 | 2 | 4 |
2003 | 1 | 8 | 9 |
2004 | 3 | 3 | 6 |
2005 | 0 | 6 | 6 |
2006 | 1 | 4 | 5 |
2007 | 2 | 1 | 3 |
2008 | 2 | 2 | 4 |
2009 | 0 | 7 | 7 |
2010 | 1 | 8 | 9 |
2011 | 3 | 12 | 15 |
2012 | 2 | 4 | 6 |
2013 | 3 | 7 | 10 |
2014 | 1 | 8 | 9 |
2015 | 1 | 4 | 5 |
2016 | 2 | 9 | 11 |
2017 | 1 | 14 | 15 |
2018 | 2 | 11 | 13 |
2019 | 4 | 10 | 14 |
2020 | 1 | 5 | 6 |
2021 | 1 | 9 | 10 |
2022 | 0 | 3 | 3 |
2023 | 0 | 2 | 2 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024 Jan 02; 15(1):89.
-
Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies. Iran J Immunol. 2023 12 31; 20(4):410-426.
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
-
Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors. Cancer Immunol Res. 2022 12 02; 10(12):1462-1474.
-
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022 01 31; 13(1):587.
-
Phenotypic and Functional Plasticity of CXCR6+ Peripheral Blood NK Cells. Front Immunol. 2021; 12:810080.
-
Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nat Commun. 2021 09 01; 12(1):5217.
-
Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. 2021 08; 40(31):4992-5001.
-
Reversing Post-Infectious Epigenetic-Mediated Immune Suppression. Front Immunol. 2021; 12:688132.
-
Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. Br J Haematol. 2021 07; 194(1):158-167.